TY - JOUR
T1 - 272nd ENMC international workshop
T2 - 10 Years of progress - revision of the ENMC 2013 diagnostic criteria for inclusion body myositis and clinical trial readiness. 16–18 June 2023, Hoofddorp, The Netherlands
AU - the 272nd ENMC workshop participants
AU - Lilleker, James B.
AU - Naddaf, Elie
AU - Saris, Christiaan G.J.
AU - Schmidt, Jens
AU - de Visser, Marianne
AU - Weihl, Conrad C.
AU - Alexandersson, Helene
AU - Alfano, Lindsay
AU - Allenbach, Yves
AU - Badrising, Umesh
AU - Benveniste, Olivier
AU - Bhai, Salman
AU - De Bleecker, Jan
AU - Breeveld, Marie Christine
AU - Chinoy, Hector
AU - Diederichsen, Louise
AU - Dimachkie, Mazen
AU - Greenberg, Steven
AU - Johari, Mridul
AU - Lilleker, James
AU - Lindgren, Ulrika
AU - Lloyd, Tom
AU - Machado, Pedro
AU - Mozaffar, Tahseen
AU - Mischke, Roland
AU - Needham, Merrilee
AU - Nishino, Ichizo
AU - Oldfors, Anders
AU - Saris, Christiaan
AU - Stenzel, Werner
AU - Tasca, Giorgio
AU - Weihl, Conrad
N1 - Publisher Copyright:
© 2024
PY - 2024/4
Y1 - 2024/4
N2 - Since the publication of the 2013 European Neuromuscular Center (ENMC) diagnostic criteria for Inclusion Body Myositis (IBM), several advances have been made regarding IBM epidemiology, pathogenesis, diagnostic tools, and clinical trial readiness. Novel diagnostic tools include muscle imaging techniques such as MRI and ultrasound, and serological testing for cytosolic 5′-nucleotidase-1A antibodies. The 272nd ENMC workshop aimed to develop new diagnostic criteria, discuss clinical outcome measures and clinical trial readiness. The workshop started with patient representatives highlighting several understudied symptoms and the urge for a timely diagnosis. This was followed by presentations from IBM experts highlighting the new developments in the field. This report is composed of two parts, the first part providing new diagnostic criteria on which consensus was achieved. The second part focuses on the use of outcome measures in clinical practice and clinical trials, highlighting current limitations and outlining the goals for future studies.
AB - Since the publication of the 2013 European Neuromuscular Center (ENMC) diagnostic criteria for Inclusion Body Myositis (IBM), several advances have been made regarding IBM epidemiology, pathogenesis, diagnostic tools, and clinical trial readiness. Novel diagnostic tools include muscle imaging techniques such as MRI and ultrasound, and serological testing for cytosolic 5′-nucleotidase-1A antibodies. The 272nd ENMC workshop aimed to develop new diagnostic criteria, discuss clinical outcome measures and clinical trial readiness. The workshop started with patient representatives highlighting several understudied symptoms and the urge for a timely diagnosis. This was followed by presentations from IBM experts highlighting the new developments in the field. This report is composed of two parts, the first part providing new diagnostic criteria on which consensus was achieved. The second part focuses on the use of outcome measures in clinical practice and clinical trials, highlighting current limitations and outlining the goals for future studies.
KW - Clinical trials
KW - Diagnostic criteria
KW - Inclusion body myositis
KW - Outcome measures
UR - http://www.scopus.com/inward/record.url?scp=85188730585&partnerID=8YFLogxK
U2 - 10.1016/j.nmd.2024.03.001
DO - 10.1016/j.nmd.2024.03.001
M3 - Article
C2 - 38522330
AN - SCOPUS:85188730585
SN - 0960-8966
VL - 37
SP - 36
EP - 51
JO - Neuromuscular Disorders
JF - Neuromuscular Disorders
ER -